These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32839900)

  • 1. How Effective is Neoadjuvant Endocrine Therapy (NET) in Downstaging the Axilla and Achieving Breast-Conserving Surgery?
    Montagna G; Sevilimedu V; Fornier M; Jhaveri K; Morrow M; Pilewskie ML
    Ann Surg Oncol; 2020 Nov; 27(12):4702-4710. PubMed ID: 32839900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy.
    Petruolo OA; Pilewskie M; Patil S; Barrio AV; Stempel M; Wen HY; Morrow M
    Ann Surg Oncol; 2017 Sep; 24(9):2556-2562. PubMed ID: 28560596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Age on Outcomes After Neoadjuvant Chemotherapy for Breast Cancer.
    Verdial FC; Mamtani A; Pawloski KR; Sevilimedu V; D'Alfonso TM; Zhang H; Gemignani ML; Barrio AV; Morrow M; Tadros AB
    Ann Surg Oncol; 2022 Jun; 29(6):3810-3819. PubMed ID: 35246810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How Often Does Modern Neoadjuvant Chemotherapy Downstage Patients to Breast-Conserving Surgery?
    Petruolo O; Sevilimedu V; Montagna G; Le T; Morrow M; Barrio AV
    Ann Surg Oncol; 2021 Jan; 28(1):287-294. PubMed ID: 32514804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer: Effects of Age and Tumor Ki67.
    Boughey JC; Hoskin TL; Goetz MP
    Ann Surg Oncol; 2022 Sep; 29(9):5747-5756. PubMed ID: 35569077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial.
    Boughey JC; McCall LM; Ballman KV; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Flippo-Morton T; Hunt KK
    Ann Surg; 2014 Oct; 260(4):608-14; discussion 614-6. PubMed ID: 25203877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes.
    Cao L; Sugumar K; Keller E; Li P; Rock L; Simpson A; Freyvogel M; Montero AJ; Shenk R; Miller ME
    Ann Surg Oncol; 2021 Oct; 28(10):5730-5741. PubMed ID: 34342757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rate and predictors of nodal pathological complete response following neoadjuvant endocrine treatment in clinically biopsy-proven node-positive breast cancer patients.
    Schipper RJ; de Bruijn A; Voogd AC; Bloemen JG; Van Riet YE; Vriens BEP; Smidt ML; Siesling S; van der Sangen MJC; Nieuwenhuijzen GAP
    Eur J Surg Oncol; 2021 Aug; 47(8):1928-1933. PubMed ID: 34030918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant Chemotherapy for Breast Cancer In the Elderly: Are We Accomplishing Our Treatment Goals?
    Williams AD; Dang CT; Sevilimedu V; Morrow M; Barrio AV
    Ann Surg Oncol; 2022 Dec; 29(13):8002-8011. PubMed ID: 35871672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axillary Downstaging in Occult Primary Breast Cancer After Neoadjuvant Chemotherapy.
    Botty Van den Bruele A; Lavery J; Plitas G; Pilewskie ML
    Ann Surg Oncol; 2021 Feb; 28(2):968-974. PubMed ID: 32813202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of Nodal Pathological Complete Response in Asian Women with Stage II-III Node-Positive Breast Cancer.
    Montagna G; Tong Y; Ritter M; Levi J; Weber WP; Chen X; Shen K
    Oncology; 2021; 99(6):359-364. PubMed ID: 33735903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of neoadjuvant versus adjuvant chemotherapy for hormone receptor-positive breast cancer: a National Cancer Database (NCDB) study.
    Zeidman M; Alberty-Oller JJ; Ru M; Pisapati KV; Moshier E; Ahn S; Mazumdar M; Port E; Schmidt H
    Breast Cancer Res Treat; 2020 Nov; 184(1):203-212. PubMed ID: 32740807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study.
    Mamtani A; Barrio AV; King TA; Van Zee KJ; Plitas G; Pilewskie M; El-Tamer M; Gemignani ML; Heerdt AS; Sclafani LM; Sacchini V; Cody HS; Patil S; Morrow M
    Ann Surg Oncol; 2016 Oct; 23(11):3467-3474. PubMed ID: 27160528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
    Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
    Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery.
    Tadros AB; Yang WT; Krishnamurthy S; Rauch GM; Smith BD; Valero V; Black DM; Lucci A; Caudle AS; DeSnyder SM; Teshome M; Barcenas CH; Miggins M; Adrada BE; Moseley T; Hwang RF; Hunt KK; Kuerer HM
    JAMA Surg; 2017 Jul; 152(7):665-670. PubMed ID: 28423171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
    Hayashi N; Takahashi Y; Matsuda N; Tsunoda H; Yoshida A; Suzuki K; Nakamura S; Yamauchi H
    Clin Breast Cancer; 2018 Apr; 18(2):e219-e229. PubMed ID: 29138067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors affecting locoregional recurrence in breast cancer patients undergoing surgery following neoadjuvant treatment.
    Chou HH; Chung WS; Ding RY; Kuo WL; Yu CC; Tsai HP; Shen SC; Chu CH; Lo YF; Chen SC
    BMC Surg; 2021 Mar; 21(1):160. PubMed ID: 33757489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer subtypes affect the nodal response after neoadjuvant chemotherapy in locally advanced breast cancer: Are we ready to endorse axillary conservation?
    Cerbelli B; Botticelli A; Pisano A; Campagna D; De Vincentiis L; Pernazza A; Frusone F; Scavina P; Monti M; Fortunato L; Costarelli L; d'Amati G
    Breast J; 2019 Mar; 25(2):273-277. PubMed ID: 30734420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nodal positivity and systemic therapy among patients with clinical T1-T2N0 human epidermal growth factor receptor-positive breast cancer: Results from two international cohorts.
    Weiss A; Martínez-Sáez O; Waks AG; Laws A; McGrath M; Tarantino P; Portnow L; Winer E; Rey M; Tapia M; Prat A; Partridge AH; Tolaney SM; Cejalvo JM; Mittendorf EA; King TA
    Cancer; 2023 Jun; 129(12):1836-1845. PubMed ID: 36951169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of neoadjuvant chemotherapy on pathologic axillary nodal status in HER-2 positive patients presenting with clinically node-negative disease.
    Al-Hilli Z; Hieken TJ; Hoskin TL; Heins CN; Boughey JC
    J Surg Oncol; 2015 Oct; 112(5):453-7. PubMed ID: 26345596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.